Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06785012 · ClinicalTrials.gov registry record · Phase 2
A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder
A Phase 2 study of Depressive Disorder, Major, sponsored by Janssen Research & Development.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 124
- Enrollment target
- 20
- Study locations
NCT06785012: Recruiting Phase 2 study of Depressive Disorder, Major, sponsored by Janssen Research & Development.
NCT06785012 is a Phase 2 study of Depressive Disorder, Major that is actively recruiting participants, run by Janssen Research & Development. The registered enrollment target is 124 participants, below the 240-participant average among 52 other Depressive Disorder, Major trials with a reported enrollment target (48% lower). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06785012, a Phase 2 study of Depressive Disorder, Major, is actively recruiting participants, sponsored by Janssen Research & Development.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 124 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate how well JNJ-89495120 works (anti-depressant effects) and how well it is tolerated as compared to placebo on reducing the symptoms of depression in participants with major depressive disorder (MDD).
Primary Outcome
The MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The scale consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG JNJ-89495120
Study Locations (20)
California
- CI Trials - Bellflower
- Wake Research PRI Encino - Encino
- National Institute Of Clinical Research - Garden Grove
- WR-Newport Beach - Newport Beach
- ATP Clinical Research - Orange
- Anderson Clinical Research - Redlands
- Artemis Institute for Clinical Research - San Diego
- Lumos Clinical Research Center LLC - San Jose
- Syrentis Clinical Research - Santa Ana
- Inland Psychiatric Medical Group Inc - Temecula
- Sunwise Clinical Research - Walnut Creek
Arizona
- Chandler Clinical Trials - Chandler
- IMA Clinical Research PC Phoenix - Phoenix
- Noble Clinical Research - Tucson
- University of Arizona - Tucson
Florida
- Gulfcoast Medical Research Center - Fort Myers
- The Medici Medical Research - Hollywood
- Advanced Research Institute of Miami - Homestead
Alabama
- UAB Huntsville Regional Medical Campus - Huntsville
Colorado
- Mountain View Clinical Research - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2024-12-26 |
| Est. Completion | 2026-06-26 |
| Phase | Phase 2 |
What NCT06785012 shows while recruiting
NCT06785012 is an interventional study that assigns participants to a tested intervention. The registered 124 participants enrollment target is mid-sized for trials with a published cap, below the 240-participant average among 52 other Depressive Disorder, Major trials with a reported enrollment target (48% lower).
The record links to 1 condition, with Depressive Disorder, Major appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06785012 names 20 study sites across 5 states, led by California, Arizona, Florida.
Frequently Asked Questions
What is clinical trial NCT06785012 about?
NCT06785012 is a clinical study titled "A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder". The purpose of this study is to evaluate how well JNJ-89495120 works (anti-depressant effects) and how well it is tolerated as compared to placebo on reducing the symptoms of depression in participants with major depressive disorder (MDD).
What is the current status of trial NCT06785012?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 124 participants. The study started on 2024-12-26. Estimated completion is 2026-06-26.
What conditions does trial NCT06785012 study?
This clinical trial studies the following conditions: Depressive Disorder, Major.
What interventions are being tested in trial NCT06785012?
The interventions under investigation include: Placebo (DRUG), JNJ-89495120 (DRUG).
Who is sponsoring clinical trial NCT06785012?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06785012 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depressive Disorder, Major
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06785012's enrollment target sits among peer trials
124 27th of 52 higher than 26 of 52 other Depressive Disorder, Major trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Depressive Disorder, Major trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Cognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab
RECRUITING · Phase 2
-
Pharmaco-Neuroimaging Studies of Approach/Avoidance Behaviors and Post-Mortem Studies: Pharmacological Manipulation
RECRUITING · Phase 2
-
Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression
RECRUITING · Phase 2
-
Individualized Functional Connectivity Targeting in aiTBS for Depression
ACTIVE NOT RECRUITING · Phase 2
-
OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult Females
COMPLETED · Phase 2
-
A Safety, Efficacy and Tolerability Study of SEP-225289
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523014 · 124 participants · Phase 2
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
- NCT02670707 · 124 participants · Phase 3
Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)
- NCT02830724 · 124 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
- NCT04748809 · 124 participants · NA
Effect of Anti-inflammatory Diet in Rheumatoid Arthritis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI